ProfileGDS5678 / 1423724_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 88% 89% 90% 89% 90% 86% 88% 89% 89% 89% 89% 89% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0229689
GSM967853U87-EV human glioblastoma xenograft - Control 26.9364688
GSM967854U87-EV human glioblastoma xenograft - Control 37.0336189
GSM967855U87-EV human glioblastoma xenograft - Control 47.4563590
GSM967856U87-EV human glioblastoma xenograft - Control 57.0508789
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9914990
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3271286
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7666988
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0007189
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1110489
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9968389
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0621289
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0774389
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1847390